Literature DB >> 7530483

Rhabdoid tumor of the kidney with primitive neuroectodermal tumor of the central nervous system: associated tumors with different histologic, cytogenetic, and molecular findings.

D W Fort1, V S Tonk, G E Tomlinson, C F Timmons, N R Schneider.   

Abstract

Rhabdoid tumor of the kidney (RTK) is associated with tumors of the central nervous system (CNS) in approximately 15% of cases. We describe the clinical features, histologic and cytogenetic findings, and molecular analysis of renal and CNS tumors from the same patient. The histology of the renal tumor was consistent with rhabdoid tumor. The CNS tumor was a primitive neuroectodermal tumor (PNET). The karyotype of the RTK was normal male. The PNET of the brain demonstrated monosomy 22 as the only cytogenetic abnormality, similar to reported cases of malignant rhabdoid tumor of the brain, but dissimilar to nonrandom cytogenetic findings in other CNS PNETs. Molecular cytogenetic and DNA marker studies confirmed loss of chromosome 22 in this patient's brain tumor. DNA allelotyping showed retention of both parental chromosome 22 alleles in the RTK and loss of the maternal allele in the PNET. Evaluation of additional RTKs and brain tumors occurring in the same patient may provide insight into the origins and relationships of these enigmatic tumors.

Entities:  

Mesh:

Year:  1994        PMID: 7530483     DOI: 10.1002/gcc.2870110303

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father.

Authors:  Ewa Izycka-Swieszewska; Maria Debiec-Rychter; Bartosz Wasag; Agnieszka Wozniak; Dariusz Gasecki; Katarzyna Plata-Nazar; Jacek Bartkowiak; Jerzy Lasota; Janusz Limon
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

2.  Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.

Authors:  Emilia M Pinto; Dima Hamideh; Armita Bahrami; Brent A Orr; Tong Lin; Stanley Pounds; Gerard P Zambetti; Alberto S Pappo; Amar Gajjar; Sameer Agnihotri; Alberto Broniscer
Journal:  Acta Neuropathol       Date:  2018-02-10       Impact factor: 17.088

3.  Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene.

Authors:  M D Taylor; N Gokgoz; I L Andrulis; T G Mainprize; J M Drake; J T Rutka
Journal:  Am J Hum Genet       Date:  2000-03-14       Impact factor: 11.025

4.  Simultaneous presentation of atypical teratoid/rhabdoid tumor in siblings.

Authors:  F Proust; A Laquerriere; B Constantin; M M Ruchoux; J P Vannier; P Fréger
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

5.  Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers.

Authors:  N Sévenet; E Sheridan; D Amram; P Schneider; R Handgretinger; O Delattre
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

Review 6.  Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature.

Authors:  J M Hilden; J Watterson; D C Longee; C L Moertel; M E Dunn; J Kurtzberg; B W Scheithauer
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

7.  Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification.

Authors:  Hironori Fujisawa; Yasushi Takabatake; Toshio Fukusato; Osamu Tachibana; Yoshitake Tsuchiya; Junkoh Yamashita
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

Review 8.  Case-based review: atypical teratoid/rhabdoid tumor.

Authors:  Cody L Nesvick; Amulya A Nageswara Rao; Aditya Raghunathan; Jaclyn A Biegel; David J Daniels
Journal:  Neurooncol Pract       Date:  2018-10-05

9.  hSNF5 /INI1 mutation analysis in acute myeloid leukemia.

Authors:  Yu-Chieh Su; Chao-Bin Chen; Ya-Ting Chang; Ya-Ting Tung; Dian-Kun Li
Journal:  Int J Hematol       Date:  2008-02-13       Impact factor: 2.490

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.